SCHEMBL6629783

SCHEMBL6629783

CCCC(CC(=O)O)(C(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
ALDH1A1 P00352 3/20 0.42
LMNA P02545 1/20 0.42
HMGCR P04035 1/20 0.40
CHRM1 P11229 1/20 0.40
TBXA2R P21731 1/20 0.40
ADRA1A P35348 1/20 0.40
FFAR1 O14842 1/20 0.39
CPT2 P23786 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
FFAR3 O14843 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031267 0.84 FFAR3 (0.38) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL8968831 0.82 TDP1 (0.48) TSHRALDH1A1FFAR1CPT2TDP1
SCHEMBL21269721 0.81 FFAR3 (0.36) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL28314587 0.81 FFAR3 (0.36) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL21269954 0.81 FFAR3 (0.36) CYP2D6TSHRCYP2C19HIF1AALDH1A1
Hydrochloric Acid SCHEMBL809273 0.81 FFAR3 (0.36) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL21269884 0.81 FFAR3 (0.36) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL1033008 0.79 ALDH1A1 (0.38) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL3178813 0.79 CYP2D6 (0.48) CYP2D6TSHRCYP2C19HIF1AALDH1A1
SCHEMBL6387474 0.78 ALDH1A1 (0.48) TSHRALDH1A1LMNAFFAR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
CN-106675755-B A kind of glass grinding fluid and preparation method thereof that can effectively disperse boron carbide abrasive material 泰伦特生物工程股份有限公司 2019-11-29 CN disclosed
EP-3508474-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR Pharmaceuticals Co., Ltd. (JP) 2019-07-10 EP disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed
US-20040231558-A1 Has a clear hue, high light fastness and high moisture resistance MITSUI CHEMICALS, INC. (JP) 2004-11-25 US disclosed
EP-1441013-A1 WATERCOLOR INK Mitsui Chemicals, Inc. (JP) 2004-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 CYP2D6 4392/4885TSHR 1657/4885CYP2C19 4497/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 CYP2D6 3259/4885TSHR 1248/4885CYP2C19 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.